O le R&D a Sorrento o loʻo taulaʻi i le faʻauluina o mea fou i le COVID-19, togafitiga o le kanesa, pulea atoatoa o tiga ma faʻamaʻi autoimmune.

Polokalama Autu	Faʻaaliga	Muamua	Vaega I	Vaega II	Vaega III/Pivotal	FDA faamaoniga
Polokalama COVID-19
COVISTIX™ (su'esu'e) Su'ega Antigen vave 0%* Fa'atonuga mo Fa'alavelave Fa'afuase'i (EUA) i Mekisiko (COFEPRIS), Pasila (ANVISA), ma le CE Fa'ailoga i Europa COVIMARK™ (su'esu'e) Su'ega Antigen vave 0%* Talosaga na tu'uina atu i le US ma Kanata mo Fa'atonu Fa'alavelave Fa'afuase'i (EUA) COVISHIELD™ (togafitiga) Fa'amama le Antibody (IN) i gasegase i fafo ma ma'i i totonu 40%* COVISHIELD™ (togafitiga) Fa'ate'aina le Antibody (IV) i gasegase i fafo ma ma'i i totonu 20%* FUJOVEE™ (Abivertinib) Tuga COVID-19 ile ICU ma'i 82%* Fa'ata'ita'iga Taua o lo'o Fa'atali le Fa'amama a le FDA OQORY™ (COVI-MSC) ARDS ona ole COVID-19 ile ICU 82%* Fa'amasinoga Taua i Pasila Mfuafuaina Taofi (pili tautala) Aneti-viral 40%* Omicron mRNA tui vasine 20%*
Polokalama Autu	Faʻaaliga	Muamua	Vaega I	Vaega II	Vaega III/Pivotal	FDA faamaoniga
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Poto 20%* FUJOVEE™ (Abivertinib) Lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *I le Paaga ma Lee's Pharm i Saina PD-L1 (STI-3031)** Kanesa Cervical 82%* **I Amerika ma faipaaga ma ImmuneOncia i Korea CD47 Tumua mautu 40%* CD38 DAR-T Umiloma Tele 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ma le esophageal 40%* TROP2 ADC* Tumua mautu 40%* * I Saina Seprehvec™ oncolytic virus Tumors Malosi; CNS Tumors 40%* BCMA ADC Tula sua 20%* Bevacizumab-ADNAB™ Endometrial Kanesa 40%* Faʻatasi ma Mayo Clinic Bevacizumab-ADNAB™ Ovarian Kanesa 40%* Faʻatasi ma Mayo Clinic Rituximab-ADNAB™ Lymphomas sela B 40%* Faʻatasi ma Mayo Clinic
Polokalama Autu	Faʻaaliga	Muamua	Vaega I	Vaega II	Vaega III/Pivotal	FDA faamaoniga
tiga
ZTlido™ 1.8% Neuralgia Postherpetic - PHN 99.8%* SP-102 (SEMDEXA) Lumbar Radicular/Sciatica tiga 82%* SP-103 (Lidocaine Topical System 5.4%) Paʻu I tua 20%* SP-104 (Naltrexone Fa'atuai Pa'u Maualalo Dose) Fibromyalgia 20%* RTX (resiniferatoxin) tui epidural Tiga e le mafai ona togafitia i le Kanesa Maualuga 60.3%* Fa'ailoga matuaoti RTX (resiniferatoxin) Auala i totonu o le tino Fa'atauva'a i le Tugā Tuli OA tiga 60.2%*
Polokalama Autu	Faʻaaliga	Muamua	Vaega I	Vaega II	Vaega III/Pivotal	FDA faamaoniga
Fa'aolaina Lymphatic
Sofusa® tetee i le TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Lymphoma T-Cell Pa'u (CTCL) 40%* Sofusa® anti-CTLA-4 Melanoma 40%* Faʻatasi ma Mayo Clinic

Polokalama COVID-19
Polokalama Autu (Fa'ailoga)	Vaega
COVISTIX™ (su'esu'e) FDA EUA COVIMARK™ (su'esu'e) FDA EUA COVISHIELD™ (togafitiga) PH I COVISHIELD™ (togafitiga) Muamua FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (pili tautala) (anti-viral) Ph I Omicron mRNA tui (tui) Muamua

immunotherapy
Polokalama Autu (Fa'ailoga)	Vaega
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II FUJOVEE™ (Abivertinib) (Prostate) Muamua FUJOVEE™ (Abivertinib) (Lupus) Muamua FUJOVEE™ (Abivertinib) (MS) Muamua FUJOVEE™ (Abivertinib) (GvHD) Muamua PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Kanesa Fa'a'au'au) Ph III CD47 (Tuma Malosi) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ma le esophageal) Ph I TROP2 ADC* (Tuma Malosi) Ph I Seprehvec™ oncolytic virus (Tumo Malosi; Pumo CNS) PH I BCMA ADC (Tumo Suava) Muamua Bevacizumab-ADNAB™ (Kanesa Fa'ama'i) Ph I Bevacizumab-ADNAB™ (Kanesa Ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I

tiga
Polokalama Autu (Fa'ailoga)	Vaega
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA faamaoniga SP-102 (SEMDEXA) Ph III SP-103 (Lidocaine Topical System 5.4%) Muamua SP-104 (Naltrexone Fa'atuai Pa'u Maualalo Dose) Muamua RTX (resiniferatoxin) tui epidural (Tiga Fa'aletonu ile Kanesa Maualuga) Ph II RTX (resiniferatoxin) Auala i totonu o le tino (Fa'alegata i le Tugā OA Tu'itu'i tiga) Ph II

Fa'aolaina Lymphatic
Polokalama Autu (Fa'ailoga)	Vaega II
Sofusa® tetee i le TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I